Essential hypertension

Summary Essential hypertension can be defined as a rise in blood pressure of unknown cause that increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of becoming hypertensive (blood pressure >140/90 mm Hg) during a lifetime exceeds 90%. Essential hypertensi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2007-08, Vol.370 (9587), p.591-603
Hauptverfasser: Messerli, Franz H, Dr, Williams, Bryan, Prof, Ritz, Eberhard, Prof
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 603
container_issue 9587
container_start_page 591
container_title The Lancet (British edition)
container_volume 370
creator Messerli, Franz H, Dr
Williams, Bryan, Prof
Ritz, Eberhard, Prof
description Summary Essential hypertension can be defined as a rise in blood pressure of unknown cause that increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of becoming hypertensive (blood pressure >140/90 mm Hg) during a lifetime exceeds 90%. Essential hypertension usually clusters with other cardiovascular risk factors such as ageing, being overweight, insulin resistance, diabetes, and hyperlipidaemia. Subtle target-organ damage such as left-ventricular hypertrophy, microalbuminuria, and cognitive dysfunction takes place early in the course of hypertensive cardiovascular disease, although catastrophic events such as stroke, heart attack, renal failure, and dementia usually happen after long periods of uncontrolled hypertension only. All antihypertensive drugs lower blood pressure (by definition) and this decline is the best determinant of cardiovascular risk reduction. However, differences between drugs exist with respect to reduction of target-organ disease and prevention of major cardiovascular events. Most hypertensive patients need two or more drugs for blood-pressure control and concomitant statin treatment for risk factor reduction. Despite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients.
doi_str_mv 10.1016/S0140-6736(07)61299-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68177424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0140673607612999</els_id><sourcerecordid>1323968321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-74811a354c5893743d53bc702d461b31ec0b14458f8ecd7192e2206a908caf953</originalsourceid><addsrcrecordid>eNqFkEtLJDEURoM42O1j604RYWRclN5UJbmVjYOIMyM0uFDBXUinbmG0uqpNqgf635t-YIMbV9mcnHw5jB1xuODA1eUDcAGZwkL9AjxXPNc601tsyAWKTAp83mbDT2TAdmN8BQChQO6wAUcERCmH7PA2Rmp7b5uTl_mUQk9t9F27z37Utol0sD732NOf28ebf9no_u_dzfUoczLHPkNRcm4LKZwsdYGiqGQxdgh5JRQfF5wcjLkQsqxLchVynVOeg7IaSmdrLYs9drbyTkP3PqPYm4mPjprGttTNolFlmipykcDTL-BrNwtt2ma4LjWWQmKC5ApyoYsxUG2mwU9smBsOZlHNLKuZRRIDaJbVjE73jtfy2XhC1ebWOlMCfq4BG51t6mBb5-OGSwMQ1YL7veIoNfvvKZjoPLWOKh_I9abq_LdTrr4YXONbnx59oznFzadNzA2sJAsH4NKgiw9WSpqP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198978457</pqid></control><display><type>article</type><title>Essential hypertension</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Messerli, Franz H, Dr ; Williams, Bryan, Prof ; Ritz, Eberhard, Prof</creator><creatorcontrib>Messerli, Franz H, Dr ; Williams, Bryan, Prof ; Ritz, Eberhard, Prof</creatorcontrib><description>Summary Essential hypertension can be defined as a rise in blood pressure of unknown cause that increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of becoming hypertensive (blood pressure &gt;140/90 mm Hg) during a lifetime exceeds 90%. Essential hypertension usually clusters with other cardiovascular risk factors such as ageing, being overweight, insulin resistance, diabetes, and hyperlipidaemia. Subtle target-organ damage such as left-ventricular hypertrophy, microalbuminuria, and cognitive dysfunction takes place early in the course of hypertensive cardiovascular disease, although catastrophic events such as stroke, heart attack, renal failure, and dementia usually happen after long periods of uncontrolled hypertension only. All antihypertensive drugs lower blood pressure (by definition) and this decline is the best determinant of cardiovascular risk reduction. However, differences between drugs exist with respect to reduction of target-organ disease and prevention of major cardiovascular events. Most hypertensive patients need two or more drugs for blood-pressure control and concomitant statin treatment for risk factor reduction. Despite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(07)61299-9</identifier><identifier>PMID: 17707755</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Antihypertensive Agents - pharmacology ; Antihypertensive Agents - therapeutic use ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Blood and lymphatic vessels ; Blood pressure ; Blood Pressure Determination - methods ; Cardiology. Vascular system ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - prevention &amp; control ; Clinical outcomes ; Dementia disorders ; Drug therapy ; General aspects ; Health risks ; Heart rate ; Humans ; Hypertension ; Hypertension - complications ; Hypertension - diagnosis ; Hypertension - drug therapy ; Hypertension - physiopathology ; Internal Medicine ; Medical practices ; Medical sciences ; Mortality ; Patients ; Reference Values ; Risk Assessment ; Risk factors ; Studies</subject><ispartof>The Lancet (British edition), 2007-08, Vol.370 (9587), p.591-603</ispartof><rights>Elsevier Ltd</rights><rights>2007 Elsevier Ltd</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Elsevier Limited Aug 18-Aug 24, 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-74811a354c5893743d53bc702d461b31ec0b14458f8ecd7192e2206a908caf953</citedby><cites>FETCH-LOGICAL-c527t-74811a354c5893743d53bc702d461b31ec0b14458f8ecd7192e2206a908caf953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/198978457?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72341</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18977765$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17707755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Messerli, Franz H, Dr</creatorcontrib><creatorcontrib>Williams, Bryan, Prof</creatorcontrib><creatorcontrib>Ritz, Eberhard, Prof</creatorcontrib><title>Essential hypertension</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Summary Essential hypertension can be defined as a rise in blood pressure of unknown cause that increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of becoming hypertensive (blood pressure &gt;140/90 mm Hg) during a lifetime exceeds 90%. Essential hypertension usually clusters with other cardiovascular risk factors such as ageing, being overweight, insulin resistance, diabetes, and hyperlipidaemia. Subtle target-organ damage such as left-ventricular hypertrophy, microalbuminuria, and cognitive dysfunction takes place early in the course of hypertensive cardiovascular disease, although catastrophic events such as stroke, heart attack, renal failure, and dementia usually happen after long periods of uncontrolled hypertension only. All antihypertensive drugs lower blood pressure (by definition) and this decline is the best determinant of cardiovascular risk reduction. However, differences between drugs exist with respect to reduction of target-organ disease and prevention of major cardiovascular events. Most hypertensive patients need two or more drugs for blood-pressure control and concomitant statin treatment for risk factor reduction. Despite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients.</description><subject>Antihypertensive Agents - pharmacology</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Blood pressure</subject><subject>Blood Pressure Determination - methods</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - prevention &amp; control</subject><subject>Clinical outcomes</subject><subject>Dementia disorders</subject><subject>Drug therapy</subject><subject>General aspects</subject><subject>Health risks</subject><subject>Heart rate</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - complications</subject><subject>Hypertension - diagnosis</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Internal Medicine</subject><subject>Medical practices</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Patients</subject><subject>Reference Values</subject><subject>Risk Assessment</subject><subject>Risk factors</subject><subject>Studies</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkEtLJDEURoM42O1j604RYWRclN5UJbmVjYOIMyM0uFDBXUinbmG0uqpNqgf635t-YIMbV9mcnHw5jB1xuODA1eUDcAGZwkL9AjxXPNc601tsyAWKTAp83mbDT2TAdmN8BQChQO6wAUcERCmH7PA2Rmp7b5uTl_mUQk9t9F27z37Utol0sD732NOf28ebf9no_u_dzfUoczLHPkNRcm4LKZwsdYGiqGQxdgh5JRQfF5wcjLkQsqxLchVynVOeg7IaSmdrLYs9drbyTkP3PqPYm4mPjprGttTNolFlmipykcDTL-BrNwtt2ma4LjWWQmKC5ApyoYsxUG2mwU9smBsOZlHNLKuZRRIDaJbVjE73jtfy2XhC1ebWOlMCfq4BG51t6mBb5-OGSwMQ1YL7veIoNfvvKZjoPLWOKh_I9abq_LdTrr4YXONbnx59oznFzadNzA2sJAsH4NKgiw9WSpqP</recordid><startdate>20070818</startdate><enddate>20070818</enddate><creator>Messerli, Franz H, Dr</creator><creator>Williams, Bryan, Prof</creator><creator>Ritz, Eberhard, Prof</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20070818</creationdate><title>Essential hypertension</title><author>Messerli, Franz H, Dr ; Williams, Bryan, Prof ; Ritz, Eberhard, Prof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-74811a354c5893743d53bc702d461b31ec0b14458f8ecd7192e2206a908caf953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antihypertensive Agents - pharmacology</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Blood pressure</topic><topic>Blood Pressure Determination - methods</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - prevention &amp; control</topic><topic>Clinical outcomes</topic><topic>Dementia disorders</topic><topic>Drug therapy</topic><topic>General aspects</topic><topic>Health risks</topic><topic>Heart rate</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - complications</topic><topic>Hypertension - diagnosis</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Internal Medicine</topic><topic>Medical practices</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Patients</topic><topic>Reference Values</topic><topic>Risk Assessment</topic><topic>Risk factors</topic><topic>Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Messerli, Franz H, Dr</creatorcontrib><creatorcontrib>Williams, Bryan, Prof</creatorcontrib><creatorcontrib>Ritz, Eberhard, Prof</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (ProQuest)</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest research library</collection><collection>ProQuest Science Journals</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Messerli, Franz H, Dr</au><au>Williams, Bryan, Prof</au><au>Ritz, Eberhard, Prof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Essential hypertension</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2007-08-18</date><risdate>2007</risdate><volume>370</volume><issue>9587</issue><spage>591</spage><epage>603</epage><pages>591-603</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Summary Essential hypertension can be defined as a rise in blood pressure of unknown cause that increases risk for cerebral, cardiac, and renal events. In industrialised countries, the risk of becoming hypertensive (blood pressure &gt;140/90 mm Hg) during a lifetime exceeds 90%. Essential hypertension usually clusters with other cardiovascular risk factors such as ageing, being overweight, insulin resistance, diabetes, and hyperlipidaemia. Subtle target-organ damage such as left-ventricular hypertrophy, microalbuminuria, and cognitive dysfunction takes place early in the course of hypertensive cardiovascular disease, although catastrophic events such as stroke, heart attack, renal failure, and dementia usually happen after long periods of uncontrolled hypertension only. All antihypertensive drugs lower blood pressure (by definition) and this decline is the best determinant of cardiovascular risk reduction. However, differences between drugs exist with respect to reduction of target-organ disease and prevention of major cardiovascular events. Most hypertensive patients need two or more drugs for blood-pressure control and concomitant statin treatment for risk factor reduction. Despite the availability of effective and safe antihypertensive drugs, hypertension and its concomitant risk factors remain uncontrolled in most patients.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>17707755</pmid><doi>10.1016/S0140-6736(07)61299-9</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 2007-08, Vol.370 (9587), p.591-603
issn 0140-6736
1474-547X
language eng
recordid cdi_proquest_miscellaneous_68177424
source MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland
subjects Antihypertensive Agents - pharmacology
Antihypertensive Agents - therapeutic use
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Blood and lymphatic vessels
Blood pressure
Blood Pressure Determination - methods
Cardiology. Vascular system
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - prevention & control
Clinical outcomes
Dementia disorders
Drug therapy
General aspects
Health risks
Heart rate
Humans
Hypertension
Hypertension - complications
Hypertension - diagnosis
Hypertension - drug therapy
Hypertension - physiopathology
Internal Medicine
Medical practices
Medical sciences
Mortality
Patients
Reference Values
Risk Assessment
Risk factors
Studies
title Essential hypertension
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A28%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Essential%20hypertension&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Messerli,%20Franz%20H,%20Dr&rft.date=2007-08-18&rft.volume=370&rft.issue=9587&rft.spage=591&rft.epage=603&rft.pages=591-603&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(07)61299-9&rft_dat=%3Cproquest_cross%3E1323968321%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198978457&rft_id=info:pmid/17707755&rft_els_id=1_s2_0_S0140673607612999&rfr_iscdi=true